Evexia Lifecare

how big is Evexia Lifecare?

As of Jun 06, Evexia Lifecare Ltd has a market capitalization of 469.33 Cr, classifying it as a Micro Cap company, with net sales of 93.25 Cr and a net profit of 1.36 Cr for the latest four quarters. The shareholder's funds are valued at 129.40 Cr, and total assets amount to 883.00 Cr as of Mar'24.

Market Cap: As of Jun 06, Evexia Lifecare Ltd has a market capitalization of 469.33 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Evexia Lifecare Ltd reported net sales of 93.25 Cr and a net profit of 1.36 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar'24. The shareholder's funds are valued at 129.40 Cr, and the total assets amount to 883.00 Cr.

Who are in the management team of Evexia Lifecare?

As of March 2022, the management team of Evexia Lifecare includes Jayesh R Thakkar (Chairman & Managing Director), Kartik Mistry, Chandresh Kumar Vishnubhai Kahar, Hasmukhbhai Thakkar, Naresh Arvindbhai Patel, Payal Gajjar (all Independent Directors), Parul Samalia (Company Secretary & Compliance Officer), and Parth Patel (Additional Director). They oversee the company's operations and governance.

As of March 2022, the management team of Evexia Lifecare includes the following individuals:<BR><BR>1. Jayesh R Thakkar - Chairman & Managing Director<BR>2. Kartik Mistry - Independent Director<BR>3. Chandresh Kumar Vishnubhai Kahar - Independent Director<BR>4. Hasmukhbhai Thakkar - Independent Director<BR>5. Naresh Arvindbhai Patel - Independent Director<BR>6. Payal Gajjar - Independent Director<BR>7. Parul Samalia - Company Secretary & Compliance Officer<BR>8. Parth Patel - Additional Director<BR><BR>This team is responsible for overseeing the company's operations and governance.

What does Evexia Lifecare do?

Evexia Lifecare Ltd operates in the edible oil industry as a micro-cap company, with a market cap of Rs 469 Cr and reported net sales of 24 Cr and net profit of 0 Cr for the quarter ending March 2025. The company was renamed from Jal Hi Power Petrochem Limited in December 2020.

Overview:<BR>Evexia Lifecare Ltd operates in the edible oil industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Jal Hi Power Petrochem Limited in 1990, underwent several name changes, and was most recently renamed Evexia Lifecare Limited on December 01, 2020. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 24 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 469 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 344.00<BR>- Industry P/E: 20<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.87<BR>- Return on Equity: 0.31%<BR>- Price to Book: 1.07<BR><BR>Contact Details:<BR>- Address: Village - Tundao, Tal Savli Vadodara Gujarat : 391775<BR>- Phone: 91-265-2362200/2361100<BR>- Email: kavitindustrieslimited@gmail.com<BR>- Website: http://www.evexialifecare.com

What is the bonus history of the Evexia Lifecare?

Evexia Lifecare issued a bonus on October 23, 2015, in a 1:3 ratio, granting one additional share for every three shares held, with the record date set for October 26, 2015.

Evexia Lifecare has a bonus history that includes a notable issue on October 23, 2015. The company announced a bonus in a ratio of 1:3, meaning that for every three shares held, shareholders received one additional share. The record date for this bonus was October 26, 2015, which is when the eligibility for receiving the bonus shares was determined. If you have any more questions about Evexia Lifecare or need further details, feel free to ask!

Has Evexia Lifecare declared dividend?

No Dividend History Available

Who are the peers of the Evexia Lifecare?

Evexia Lifecare's peers include Marico, Patanjali Foods, AWL Agri Business, Gokul Agro, and others. While Marico shows excellent management risk and capital structure, Evexia Lifecare has below-average growth and capital structure, with a 1-year return of 1.23%.

Peers: The peers of Evexia Lifecare are Marico, Patanjali Foods, AWL Agri Busine., Gokul Agro, Sundrop Brands, Gokul Refoils, Shri Venkatesh, Ajanta Soya, Vijay Solvex, and M K Proteins.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marico, while Average management risk is found at Patanjali Foods, Gokul Agro, Sundrop Brands, Shri Venkatesh, Ajanta Soya, and Vijay Solvex, and the rest. Below Average management risk is seen at AWL Agri Busine., Gokul Refoils, and M K Proteins. Growth is Excellent at Patanjali Foods and Gokul Agro, Good at AWL Agri Busine. and the rest, while Below Average growth is noted at Marico, Sundrop Brands, Gokul Refoils, Evexia Lifecare, Shri Venkatesh, Ajanta Soya, Vijay Solvex, and M K Proteins. Capital Structure is Excellent at Marico and Ajanta Soya, Good at Patanjali Foods, AWL Agri Busine., Gokul Agro, and Vijay Solvex, while Below Average is observed at Gokul Refoils, Evexia Lifecare, Shri Venkatesh, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shri Venkatesh at 93.70%, while the lowest is AWL Agri Busine. at -27.15%. Evexia Lifecare's 1-year return is 1.23%, which is significantly lower than both extremes. Additionally, Gokul Refoils, Evexia Lifecare, AWL Agri Busine., and M K Proteins have negative six-month returns.

What is the technical trend for Evexia Lifecare?

As of June 2, 2025, Evexia Lifecare's trend has shifted to bearish with moderate strength, supported by bearish indicators from moving averages and Bollinger Bands, despite mixed signals from the KST and MACD.

As of 2 June 2025, the technical trend for Evexia Lifecare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the negative trend. Daily moving averages are also bearish, suggesting continued downward pressure. The KST shows mixed signals with a mildly bullish weekly reading and a mildly bearish monthly reading. Overall, the lack of clear signals from the RSI and Dow Theory indicates a weak trend, further supporting the bearish outlook.

Who are the top shareholders of the Evexia Lifecare?

The top shareholders of Evexia Lifecare include Aio Growth Capital Fund Spc at 12.17%, Raghuvir International at 1.55%, and individual investors holding 36.68%. There is minimal mutual fund and foreign institutional investor involvement, with no pledged promoter holdings.

The top shareholders of Evexia Lifecare include a mix of individual and institutional investors. The largest public shareholder is Aio Growth Capital Fund Spc, holding 12.17%. Among the promoters, Raghuvir International has the highest holding at 1.55%. Additionally, individual investors collectively hold a significant portion, accounting for 36.68% of the shares. The company also has some mutual fund involvement, with three schemes holding a total of 0.02%, and one foreign institutional investor (FII) holding 0.16%. Notably, there are no pledged promoter holdings.

Are Evexia Lifecare latest results good or bad?

Evexia Lifecare's latest results are concerning, with a 63.70% drop in Profit After Tax and a 5.2% decrease in net sales, leading to a 'Strong Sell' rating from MarketsMOJO. While cash reserves are at a three-year high, the overall performance is considered bad due to declining sales and profitability.

Evexia Lifecare's latest financial results indicate a challenging situation for the company. The overall performance has been flat, with a significant decline in key metrics. The Profit After Tax (PAT) for the nine-month period has dropped by 63.70% year-on-year, standing at Rs 1.06 crore. Additionally, net sales for the quarter were reported at Rs 22.09 crore, which is a decrease of 5.2% compared to the previous four quarters.<BR><BR>While there is a positive aspect in that cash and cash equivalents have reached Rs 5.27 crore, the highest level in the last three years, this does not offset the concerning trends in sales and profitability. The stock has also been rated as a 'Strong Sell' by MarketsMOJO, reflecting the financial challenges the company is currently facing. Overall, the results can be characterized as bad, given the declines in both sales and profitability.

Is Evexia Lifecare overvalued or undervalued?

As of October 23, 2025, Evexia Lifecare is considered overvalued with a high PE ratio of 212.41 and an EV to EBITDA ratio of 206.57, significantly contrasting with its peers, and has underperformed the market with a year-to-date decline of 42.61%.

As of 23 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, based on the current financial metrics, the company remains overvalued. The PE ratio stands at an exceptionally high 212.41, while the EV to EBITDA ratio is also elevated at 206.57, suggesting that the market is pricing in significant growth expectations that may not be justified by the company's performance.<BR><BR>In comparison to its peers, Evexia Lifecare's ratios starkly contrast with those of Gulf Oil Lubricants and Veedol Corporation, which have PE ratios of 16.16 and 16.62, respectively, and EV to EBITDA ratios of 10.99 and 14.69. These peers are classified as very attractive, highlighting the disparity in valuation. Furthermore, Evexia's return metrics are concerning, with a year-to-date decline of 42.61%, significantly underperforming the Sensex's 8.21% gain during the same period. This underperformance reinforces the view that Evexia Lifecare is overvalued in the current market environment.

When is the next results date for Evexia Lifecare?

The next results date for Evexia Lifecare is 14 November 2025.

The next results date for Evexia Lifecare is scheduled for 14 November 2025.

How has been the historical performance of Evexia Lifecare?

Evexia Lifecare's historical performance shows significant sales growth from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, despite previous declines. While operating profit improved, profitability metrics decreased, and total liabilities rose, indicating a mixed financial outlook.

Answer:<BR>The historical performance of Evexia Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Evexia Lifecare's net sales increased from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, marking a substantial growth. However, net sales had previously declined from 69.55 Cr in Mar'23 to 56.29 Cr in Mar'24. The total operating income followed a similar trend, rising to 110.48 Cr in Mar'25 from 56.29 Cr in Mar'24, after a dip in the preceding years. The total expenditure, excluding depreciation, also increased to 106.40 Cr in Mar'25 from 54.31 Cr in Mar'24, reflecting higher costs associated with the increased sales. Operating profit (PBDIT) improved to 4.22 Cr in Mar'25 from 2.85 Cr in Mar'24, indicating better operational efficiency. Profit before tax showed a slight decrease to 1.44 Cr in Mar'25 from 1.93 Cr in Mar'24, while profit after tax also declined to 0.93 Cr in Mar'25 from 1.38 Cr in Mar'24. The company's total liabilities rose to 883.00 Cr in Mar'24 from 847.50 Cr in Mar'23, with long-term borrowings remaining significant at 676.64 Cr in Mar'24. Cash flow from operating activities improved to 17.00 Cr in Mar'24, contrasting with a negative cash flow in the previous year, while cash flow from investing activities saw a substantial outflow of -17.00 Cr in Mar'24. Overall, Evexia Lifecare's financial performance reflects a recovery in sales and operational profit, despite challenges in profitability and increasing liabilities.

Should I buy, sell or hold Evexia Lifecare?

Why is Evexia Lifecare Ltd falling/rising?

As of 07-Feb, Evexia Lifecare Ltd's stock price is 1.64, unchanged from the previous session, and has declined 45.15% over the past year, indicating weak investor confidence. Despite a slight short-term outperformance, the stock shows bearish trends and poor fundamentals, including a significant drop in profit and low return on equity.

As of 07-Feb, Evexia Lifecare Ltd's stock price is currently at 1.64, with no change from the previous trading session. The stock has shown a mixed performance over various periods, with a notable decline of 45.15% over the past year, while the benchmark Sensex has increased by 7.07% during the same timeframe. This significant underperformance indicates a lack of investor confidence in the company's long-term prospects.<BR><BR>In the short term, the stock has outperformed its sector by 0.27% today, but this is overshadowed by a concerning trend of falling investor participation, as evidenced by a 41.68% drop in delivery volume compared to the 5-day average. Additionally, while the stock is trading higher than its 5-day moving averages, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend.<BR><BR>The company's fundamentals are weak, with a negative compound annual growth rate (CAGR) of -1.85% in net sales over the last five years and a high debt to EBITDA ratio of -1.00 times, indicating difficulties in servicing debt. The return on equity is also low at an average of 0.88%, reflecting poor profitability. Furthermore, the recent financial results showed a significant decline in profit after tax, which fell by 66.50%, and the operating profit to net sales ratio reached its lowest point at 0.43%.<BR><BR>Overall, the combination of weak financial performance, declining investor participation, and poor long-term growth prospects contributes to the stock's downward trajectory.

Which are the latest news on Evexia Lifecare?